Zyrorab D 30mg/20mg Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying or gastroparesis. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing symptomatic relief in acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance through reduced dosing frequency. Zyrorab D is indicated for patients requiring combined prokinetic and acid suppression therapy, optimizing symptom control and mucosal healing. It should be administered under medical supervision, with caution advised in patients with cardiac arrhythmias, hepatic impairment, or known hypersensitivity to either component. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Drug interactions should be carefully evaluated, particularly with medications metabolized via CYP3A4. Zyrorab D 30mg/20mg Capsule SR offers a synergistic approach for comprehensive management of upper gastrointestinal motility and acid-related disorders.